Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Skin probiotics to treat Netherton Syndrome

Award Number: R43AR082240
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2022
PERIOD OF PERFORMANCE END DATE: 08/31/2023

Group Awards By:

View Award Description

Skin probiotics to treat Netherton Syndrome - Project Summary Netherton syndrome (NS) is a severe genetic disorder that affects the skin, hair, and immune system. NS is caused by mutations associated with the SPINK5 gene which encodes LEKTI (Lympho-epithelial Kazal-type inhibitor), a serine protease inhibitor. Normally, skin shedding is controlled by an extracellular balance between serine proteases and serine protease inhibitors, and mutations in LEKTI result in overactivity of serine proteases. There is not an FDA-approved therapy or consensus treatment of conditions, and symptoms are mostly managed through antibacterials, emollients and corticosteroids. An enzyme-replacement therapy of topically applied LEKTI could be an elegant solution, but the short half-life of LEKTI precludes this possibility. The skin microbiome is home to over 1011 bacteria, and provides an attractive target as a delivery vehicle through continuous delivery of LEKTI. Through synthetic biology, we will engineer a bacteria to colonize the skin surface and secrete bioactive LEKTI to restore balance to the skin shedding process. In this Phase I SBIR, we will establish the safety of our topical application in in vitro models and demonstrate bioactive secretion of LEKTI fragments. This will provide a strong foundation to transition to Phase 2 where we will establish safety and efficacy in murine genetic models.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	RESVITA BIO INC	1261 64TH ST	EMERYVILLE	CA	94608	ALAMEDA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	4/23/2024	NEW	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $249,935 )
2022	2022	RESVITA BIO, INC.	1261 64TH ST APT B	EMERYVILLE	CA	94608	ALAMEDA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	9/9/2022	NEW	$249,935
														Subtotal = $249,935

Grand Total All Awards = $249,935

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Skin probiotics to treat Netherton Syndrome

Award Number: R43AR082240

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2022

PERIOD OF PERFORMANCE END DATE: 08/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer